KYORIN Pharmaceutical Co.,Ltd. · TSE:4569
KYORIN Pharmaceutical Co.,Ltd — H1 FY2023 Earnings Presentation
34 slides from KYORIN Pharmaceutical Co.,Ltd's earnings presentation, Nov 9, 2023
Slide 1: Interim Term Financial Results Ended September 2023
Interim Term Financial Results Ended September 2023 November 9 , 2023 KYORIN Pharmaceutical Co., Ltd. Representative Director, President and CEO Yutaka Ogihara 1
Slide 2: Outline of Consolidated Financial Results
Outline of Consolidated Financial Results Trends of mainstay products, generic product Consolidated Financial Forecast Status of R&D Pipeline Overview of the Midium-term Vision “Vision 110 –Stage 1–” 2
Slide 3: Outline of Consolidated Financial Results
Outline of Consolidated Financial Results 3
Slide 4: Breakdown of Gain and Loss for Second quarter of FY2023
Breakdown of Gain and Loss for Second quarter of FY2023 (Units: JPY billions) Year-on-year Vs forecast (announced on May 11, 2023) FY2022 2Q FY2023 2Q Change Change (%) Change Net Sales 49.1 54.9 +5.8 +11.9 +1.2 New drugs, etc. (Japan) 32.7 37.9 +5.2 +16.0 + 1.2 New drugs (Overseas) 0.3 0.2 -0.1 -46
Slide 5: Highlights of Business Performance (1/3) YoY: Net Sales
Highlights of Business Performance (1/3) YoY: Net Sales (Units: JPY billions) 60.0 54.9 [Net Sales +5.8 bln] 49.1 50.0 New drugs, etc. (Japan) + 5.2 16.9 ⚫ NHI drug price revision (KYORIN Pharm: 7% range) 40.0 16.1 ⚫ Mainstay drugs grew 0.2 0.3 New drugs (Overseas) 30.0 -0.1 20.0 37.9 Generic drugs
Slide 6: Highlights of Business Performance (2/3) YoY: Operating Profit
Highlights of Business Performance (2/3) YoY: Operating Profit (Units: JPY billions) 3.5 [Operation profit +0.3 bln] 3 -0.7 Gross profit + 2.0 Net sales + 5.8 bln 2.5 +2.4 Cost of sales ratio + 1.0 %pt Factor of New drugs (Beova, Lasvic etc) grew 2 Decrease Factor of NHI drug price revision (KYORIN
Slide 7: Highlights of Business Performance (3/3) vs Forecast
Highlights of Business Performance (3/3) vs Forecast (Units: JPY billions) Year-on-year vs forecast (announced on May 11, 2023) FY2022 2Q FY2023 2Q Change Change (%) Change Net Sales 49.1 54.9 +5.8 +11.9 +1.2 New drugs, etc. (Japan) 32.7 37.9 +5.2 +16.0 + 1.2 New drugs (Overseas) 0.3 0.2 -0.1 -46.5
Slide 8: FY2023 2Q Mainstay Product Sales Update
FY2023 2Q Mainstay Product Sales Update (Units: JPY billions) Year-on-year vs Forecast FY2022 2Q FY2023 2Q (announced on May 11, 2023) Change Change (%) Change Beova (KYORIN) (β3 adrenergic receptor agonist overactive bladder therapeutics ) 5.5 8.3 +2.8 +50.8 -0.5 Lasvic (New quinolone synthetic ant
Slide 9: Trends of Mainstay Products and Generic Drugs
Trends of Mainstay Products and Generic Drugs 9
Slide 10: [Mainstay products] Beova (Therapeutic agent for OAB)
[Mainstay products] Beova (Therapeutic agent for OAB) Anticholinergic agents β3 receptor antagonist others OAB market (Apr-Sep) Beova(KYORIN) share Sales Second half of the fiscal year First half of the fiscal year (Units: JPY billion) (%) 48.5 20.8 46.6 47.3 20 (Units: JPY billion) 43.8 45.6 20 18.
Slide 11: [Mainstay products] Lasvic (New quinolone synthetic antibacterial agent)
[Mainstay products] Lasvic (New quinolone synthetic antibacterial agent) Oral antimicrobial market (Apr-Sep) Market Lasvic share Sales Second half of the fiscal year First half of the fiscal year (Units: JPY billions) (%) 4 5.8 60.0 6 3.2 3 2.5 0.7 40.0 4 3.3 1.8 2.7 2 1.5 20.0 2 1.1 0.9 1.0 2.5 1.4
Slide 12: [Mainstay products] Lyfnua (Cough treatment)
[Mainstay products] Lyfnua (Cough treatment) The number of estimated patients 1.5 Chronic chough patients RCC/UCC patients 1.3 2,500 K 400 K ~ 500 K 1.0 0.9 Definition of Refractory/Unexplained Chronic Cough 0.5 0.2 0.5 RCC/UCC 0.1 0.4 (Forecast) 0.0 0.1 23/3 24/3 (Forecast) Status in FY2023 2Q Refr
Slide 13: [Mainstay products] Desalex (Antiallergic Agent)
[Mainstay products] Desalex (Antiallergic Agent) Antihistamine market (Apr-Sep) (Units: JPY billions) Sales Second half of the fiscal year First half of the fiscal year (Units: JPY billions) New drugs Long-listed and generic drugs Desalex share(%) 10 80.0 10.0 8.9 68.4 8.3 8.5 8 7.4 7.1 60.0 58.7 55
Slide 14: [Mainstay products] Flutiform (Anti-asthmatic)
[Mainstay products] Flutiform(Anti-asthmatic) Second half of the fiscal year ICS/LABA market (Apr-Sep) Sales First half of the fiscal year Market Flutiform share (Units: JPY billions) (Units: JPY billions) (Units: %) 14.6 60.0 20 15 16.7 13.3 15.8 15.8 12.6 12.0 15.2 11.4 15 12.6 40.0 10 7.9 6.9 6.3
Slide 15: Status of Generic Drugs
Status of Generic Drugs Sales Sales in AG (three products) among with the sales at left (Units: JPY billions) (Units: JPY billions) 40 38.2 36.6 20 34.8 18.7 32.2 16.6 31.0 15.4 14.3 14.8 30 15 22.1 19.7 19.3 11.8 16.8 17.8 10.1 20 10 8.5 9.7 7.8 16.7 10 5 6.0 14.2 14.4 15.5 16.1 16.9 (Forecast) 5.8
Slide 16: Consolidated Financial Forecast FY2023
Consolidated Financial Forecast FY2023 16
Slide 17: Consolidated Financial Forecast FY2023
Consolidated Financial Forecast FY2023 (Unit: JPY billion) Year-on-year FY2022 FY2023 Change Change (%) Net Sales 113.3 116.2 + 2.9 + 2.6 New drugs, etc. (Japan) 74.8 79.1 + 4.3 + 5.8 New drugs (Overseas) 0.3 0.4 + 0.1 + 29.6 Generic drugs 38.2 36.6 -1.6 -4.2 Cost of sales 63.1 - - - SG&A (R&D) 45.0
Slide 18: Forecast of Mainstay Products Sales
Forecast of Mainstay Products Sales (Unit: JPY billions) FY2023 Year-on-year FY2022 (Forecast) Change Change (%) Beova (KYORIN) (β3 adrenergic receptor agonist overactive bladder therapeutics ) 12.9 18.9 + 6.0 + 46.8 Lasvic (New quinolone synthetic antibacterial agent) 2.5 3.2 + 0.7 + 32.6 Lyfnua (S
Slide 19: Shareholders Returns
Shareholders Returns ● Increase capital efficiency through investment for growth and shareholder Capital returns, with a constant awareness of the cost of capital and return on capital Policy while maintaining the sound financial base. ● Maintain stable dividends taking DOE (Dividend on Equity) rati
Slide 20: Status of R&D Pipeline
Kyorin ©) | Status of R&D Pipeline
Slide 21: Status of R&D Pipeline in FY2023
Status of R&D Pipeline in FY2023 Updated Development code Ph1 Ph2 Ph3 Application Approval/Launch MRCT*1 Respiratory KRP-R120 (September 2022) Infections KRP-A218 (April 2021) (Completed Urology AKP-009*2 by ASKA) KRP-114VP (August 2022) *1 MRCT: Multi-Regional Clinical Trials *2 Ph1 trial is being
Slide 22: Development of Digital Therapeutics in Otolaryngology Field [KRP-DT123]
Development of Digital Therapeutics in Otolaryngology Field [KRP-DT123] Start of the specified clinical trial using the DTx for tinnitus Title A Multicenter, Randomized, Double-Blind, Sham-Controlled Study using the App for Tinnitus Treatment in Patients with Tinnitus (Pilot Study). Primar y Change
Slide 23: Initiative toward Realization of the Mid-term Vision Vision 110 Stage 1
Initiative toward Realization of the Midium-term Vision “Vision 110 -Stage1-” 23
Slide 24: Vision 110 -Stage 1
Vision 110 -Stage 1 1. Strengthening drug discovery capability to create high-value new drugs that meet medical needs 2. Expansion of development pipeline through in-licensing 3. Maximization of the ratio of new drugs 4. Promoting healthcare-related businesses that have synergies with the new drugs
Slide 25: Try for drug innovation through new drug discovery strategies
Vision 110 -Stage 1 Strengthening drug discovery capability to create high-value new drugs that meet medical needs Try for drug innovation through new drug discovery strategies Development of new Strengthen research themes basic technology New targets Small molecule drugs Known targets Nucleic acid
Slide 26: Maximization of the ratio of new drugs: Beova, Lasvic, Lyfnua
Vision 110 -Stage 1 Maximization of the ratio of new drugs Products Aimed status Goal at FY2025 Sales (JPY billions) ⚫ No.1 in OAB market as Beova Beova® First-line treatment for OAB ⚫ in FY2023 50% of patient’s share 56.0 ⚫ First-choice antibacterial agent for No.1 in oral new quinolone market in F
Slide 27: Ratio of new drugs grew
Vision 110 -Stage 1 Maximization of the ratio of new drugs Ratio of new drugs grew 50% and more 48.4% (Actual for 2Q) 42.0% 29.3% Desalex Beova Lasvic Lasvic Lyfnua tablet IV 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 (FY) Patent expiration of Kipres 27
Slide 28: Beova®
Vision 110 -Stage 1 Maximization of the ratio of new drugs Beova® ●New patients acquisition rate : No.1 (End of September 2023: 43.4%*1, as Beova) ●Switching rate from existing drugs: No.1 Status (End of September 2023: 35.9%*1, as Beova) Patients share of OAB market (as Beova) FY2022: 25.7%*2 => FY
Slide 29: Lasvic®
Vision 110 -Stage 1 Maximization of the ratio of new drugs Lasvic® NQ: New quinolone ●Classified Covid-19 to the Category V caused market expansion (Oral NQ market: +150%, year on year) ●Listed in guidelines as a recommended drug Status ●Growth rate of No.1 in expansion of oral NQ market GP: Promoti
Slide 30: Lyfnua®
Vision 110 -Stage 1 Maximization of the ratio of new drugs Lyfnua® ⚫ Dismantling of prescription on May 1, 2023 ⚫ Number of customers in FY2023 2Q GP Target achieved HP Target not achieved Status ⚫ Lower sales than the forecast ⇒ Period of taking drug was shorter than expected Initiatives for second
Slide 31: Construction of the Takaoka New Plant
Vision 110 -Stage 1 Promoting healthcare-related businesses that have synergies with the new drugs business Construction of the Takaoka New Plant Strengthen the supply capacity as the production of drugs increased Takaoka plant (Toyama) as of October 11, 2023 【Outline of the Takaoka Plant】 Location
Slide 32: Reform of management group structure and new initiatives
FY2023 Management policy Reform of management group structure and new initiatives Reform of R&D Expand of systems development pipeline Maximize the expansion of sales Improve cost growth in new drugs competitiveness 32
Slide 33: Disclaimer
Disclaimer This material contains performance forecasts, goals and plans, and other forward-looking statements related to the Group. These statements are based on the judgment of the Group’s assumptions and outlooks based on the information and forecasts available at the time of preparation of this
Slide 34: Kyorin ©)
Kyorin ©)
KYORIN Pharmaceutical — H1 FY2023 Earnings Presentation on 6ix